TAG:
cap
May 10, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 7 – May 10, 2010 Issue
Just four years since its founding in June, 2006, Aurora Diagnostics, Inc., of Palm Beach Gardens, Florida, is preparing to go public. On April 30, the company filed stock registration documents with the Securities and Exchange Commission (SEC) for an IPO (initial pu…
Letter to Editor on EMR Donations, Deeply-Discounted Client Prices
By Robert Michel | From the Volume XVII No. 7 – May 10, 2010 Issue
Dear Editor: Because THE DARK REPORT is willing to tackle tough issues regarding the business end of the pathology profession, I am writing to call attention to a serious situation. What follows is presented as mostly factual and minimally perceptive. While I have no fe…
French Company Buys Pittsburgh-Based RedPath
By Robert Michel | From the Volume XVII No. 7 – May 10, 2010 Issue
CEO SUMMARY: Here’s a deal that is all about proprietary molecular assays and access to new markets. With its purchase of RedPath Integrated Pathology, ExonHit Therapeutics, S.A., of Paris, France, gains a CLIA laboratory and access to the U.S. market, even as the new owner ope…
Optimism & Opportunity at Executive War College
By Robert Michel | From the Volume XVII No. 7 – May 10, 2010 Issue
CEO SUMMARY: Instead of our annual review of key speakers as a source of emerging trends and common themes, this year we assess the attitudes, opinions, and activities of the pathologists, laboratory administrators, managers, and industry executives in attendance at the 15th Annu…
ISO 15189 Accreditation Requires Specific Steps For Global Recognition
By Robert Michel | From the Volume XVII No. 6 – April 19, 2010 Issue
CEO SUMMARY: This intelligence briefing is the third in an ongoing series about quality management systems (QMS) and their role in advancing the performance of clinical laboratories and improving the quality of the testing services they provide. ISO 15189 is a set of standards for medical…
Pre-authorization Coming For Pricey Molecular Tests
By Robert Michel | From the Volume XVII No. 6 – April 19, 2010 Issue
CEO SUMMARY: In response to the steep ramp-up in the utilization of genetic and molecular testing, the nation’s largest health insurers are preparing to institute new guidelines for coverage and reimbursement. These will include pre-authorization by physicians, a more effective genetic …
March 29, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
News sources are reporting a rumor that President Barack Obama intends to appoint Donald Berwick, M.D., as Director of the Centers for Medicare and Medicaid Services (CMS). Berwick is currently Director of the Institute for Healthcare Improvement in Boston, Massachus…
Use of Point-of-Care Testing Reduces Mortality by 50%
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO Summary: In a thinly-populated region the size of Texas and New Mexico combined, an integrated clinical care program based on point-of- care testing (POCT) has delivered impressive gains in health outcomes. For rural residents, mortality rates from cardiovascular disease have fallen b…
Serious Problems Plague Newfoundland Laboratory
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO SUMMARY: Newfoundland’s St. John laboratory was rocked by revelations in February that its cyclosporine testing was flawed, exposing patients to the harmful affects from inappropriately high doses of the immunosuppressant drug. Within weeks of this news, the Chief of Laboratory Medi…
Two New Pathology Models Will Soon Be Tried in Dallas
By Robert Michel | From the Volume XVII No. 4 – March 8, 2010 Issue
CEO SUMMARY: There are notable aspects to how and why four unlikely partners are banding together to invest $40 million and create the nation’s newest reference and esoteric testing laboratory. It was the pathologists at Baylor University Hospital in Dallas, Texas, who originated the vi…
CURRENT ISSUE

Volume XXXII, No. 12 – August 25, 2025
In an exclusive interview, a laboratory industry M&A specialist discusses what’s driving lab outreach sales to national lab companies. Also, The Dark Report analyzes ways in which pathology and clinical labs can profitably partner with pharmaceutical companies.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized